医用大麻治疗儿科发育、行为和精神健康障碍。
Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders.
机构信息
Murdoch Children's Research Institute, 50 Flemington Rd, Parkville, VIC 3052, Australia.
The Royal Children's Hospital, 50 Flemington Rd, Parkville, VIC 3052, Australia.
出版信息
Int J Environ Res Public Health. 2023 Apr 7;20(8):5430. doi: 10.3390/ijerph20085430.
Parents of children with developmental, behavioural and mental health disorders are increasingly asking whether medicinal cannabis might be a therapeutic option for their child. This paper presents the current evidence for medicinal cannabis in this population. Preliminary evidence from open-label studies suggests the potential for medicinal cannabis to ameliorate some symptoms in children with autism spectrum disorder. However, only one double-blind placebo-controlled trial has been completed, with inconclusive findings. Synthetic, transdermal cannabidiol gel has demonstrated efficacy for reducing social avoidance in a sub-group of children with Fragile X syndrome. Studies of medicinal cannabis are planned or underway for children and/or adolescents with autism, intellectual disability, Tourette's syndrome, anxiety, psychosis, anorexia nervosa and a number of specific neurodevelopmental syndromes. High quality evidence from double-blind placebo-controlled trials is needed to guide clinical practice.
患有发育、行为和精神健康障碍的儿童的家长越来越多地询问大麻药用是否可能是他们孩子的一种治疗选择。本文介绍了该人群中大麻药用的现有证据。来自开放标签研究的初步证据表明，大麻药用有可能改善自闭症谱系障碍儿童的一些症状。然而，只有一项双盲安慰剂对照试验已经完成，结果尚无定论。合成透皮型大麻二酚凝胶已证明可有效减少脆性 X 综合征儿童亚组的社交回避。正在计划或正在为自闭症、智力残疾、妥瑞氏症、焦虑症、精神病、神经性厌食症和许多特定神经发育综合征的儿童和/或青少年开展大麻药用研究。需要来自双盲安慰剂对照试验的高质量证据来指导临床实践。
Zotero 插件